Hepatitis C

Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

Chronic hepatitis B patients with HBsAg <100 IU/mL and HBcrAg <3 log U/mL at nucleot(s)ide analog therapy had lower relapse risk.

Direct-acting antiviral agents have enabled more availability for organ transplant.

A study links hepatitis C infection and Parkinson's disease, identifying 19 genes with shared expression changes and highlighting sex-specific immune responses.

Liver-related mortality in the US increased by nearly 20% from 2018, with lower transplant rates observed in states with the greatest mortality.

HCV infection was associated with elevated brachial-ankle pulse wave velocity levels in patients with ESRD receiving hemodialysis.

Findings support the feasibility and clinical performance of Xpert HCV, the first FDA-approved point-of-care test for diagnosing HCV, in a nonclinical justice setting.

Findings highlight HCV infection burden among people without injection drug use, a known risk factor for HCV, and call for universal testing to better capture these individuals.

Compared with other international guidelines, the 2024 World Health Organization HBV guidelines had the highest treatment eligibility rates.

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.

Physicians who received pharmaceutical industry payments related to 4 different direct-acting antivirals were more likely to prescribe these medications.

Heplisav-B provided a greater vaccine completion rate and higher HBV seroprotection than the conventional 3-dose Recombivax HB in thoracic organ transplant candidates.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

Findings support the use of FIB-4’s low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index’s high cut-off for significant fibrosis in chronic HCV.

A study suggests transient elastography and fibrosis-4 index may be effective in predicting hepatocellular carcinoma risk in hepatitis C patients.

Data for more than 2 million blood donors in Canada provides insight into HCV antibody positivity trends in this notoriously low-risk patient population.

A new study found hepatitis C virus reinfections may occur within 24 weeks of sustained virologic response after injecting drugs.

Findings support the use of liver grafts from donation after circulatory death and HCV-positive donors, citing comparable 1-year patient and graft survival.

Findings suggest the benefit of early HCV detection and treatment with DAAs for improving liver-related outcomes and reducing fibrotic burden.

Results suggest paternal hepatitis B virus infection prior to pregnancy is associated with a 40% increased risk of congenital heart diseases in their children.

High-risk alcohol use was linked to greater rates of cirrhosis in patients with HCV but did not significantly impact rates of sustained virologic response.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.